

The Modified Phenanthridine PJ34 Unveils a Cell-Death Mechanism Exclusive to Human Cancer Cells

The post translational modification of NuMA is a new target for cancer therapy

Prof. M. Cohen-Armon
Faculty of Medicine and Sagol School of Neuroscience
Tel-Aviv University

Tricyclic molecules eradicating human cancer cells

Castiel et al. *BMC Cancer* 2011, 11:412
http://www.biomedcentral.com/1471-2407/11/412





RESEARCH ARTICLE

Open Access


A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells

Asher Castiel^{4†}, Leonid Visochek^{1†}, Leonid Mittelman³, Françoise Dantzer⁵, Shai Izraeli^{2,4} and Malka Cohen-Armon^{1*}



Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity

Ying-Ying Wang,¹ Tsuyoshi Taniguchi,² Tomohisa Baba,¹ Ying-Yi Li,^{1,3,4} Hiroyuki Ishibashi² and Naofumi Mukaida^{1,5}




Antineoplastic Properties of THCV, HHC and their anti-Proliferative effects on HPAF-II, MIA-paca2, Aspc-1, and PANC-1 PDAC Pancreatic Cell Lines

Tesfay T. Tesfatsion¹, Arianna C. Collins¹, Giovanni A. Ramirez¹, Yousef Mzannar², Husain Yar Khan², Omar Aboukameel², Asfar S. Azmi², Prakash G. Jagtap¹, Kyle P. Ray^{1,3}, Westley Cruces^{1,3}

¹ Colorado Chromatography Labs LLC., 10505 S Progress Way Unit 105 Parker CO 80134

² Karmanos Cancer Institute, Wayne State University, 4100 John R. St, Detroit, MI 48201

³ BlackStone Therapeutics, 10505 S Progress Way Unit 105 Parker CO 80134




Article




THE
EMBO
JOURNAL

Inhibition of CPAP–tubulin interaction prevents proliferation of centrosome-amplified cancer cells

Aruljothi Mariappan^{1,2}, Komal Soni^{3,4}, Kenji Schorpp⁵, Fan Zhao^{6,7,8}, Amin Minakar⁹, Xiangdong Zheng^{6,7,8}, Sunit Mandad^{10,11,12}, Iris Macheleidt¹³, Anand Ramani^{1,14}, Tomáš Kubelka⁴, Maciej Dawidowski^{3,4,15}, Kristina Golfmann², Arpit Wason², Chunhua Yang¹⁶, Judith Simons², Hans-Günther Schmalz⁹, Anthony A Hyman¹⁷, Ritu Aneja¹⁶, Roland Ullrich², Henning Urlaub^{10,11}, Margarete Odenthal¹³, Reinhardt Büttner¹³, Haitao Li^{6,7,8}, Michael Sattler^{3,4}, Kamyar Hadian⁵ & Jay Gopalakrishnan^{1,2,14,*}





Exclusive eradication of the indicated human malignant epithelial cells treated with PJ34 (96 hours) at the indicated concentrations. Benign human breast epithelial cells are not impaired.



PJ34 Does Not impair the Cell Cycle of proliferating healthy somatic cells

PJ34 does not affect the cell-cycle in human healthy somatic cells (breast **epithelial** cells, primary human thymus **mesenchymal** cells and human **endothelial** cells (prepared from the Human Umbilical vein) treated with PJ34 in the indicated concentration and incubation periods

Proliferation of human breast epithelial cells incubated with PJ34 at the indicated concentrations (μM) for 96 h




Castiel et al., BMC Cancer, 2011

Inbar-Rozensal et al, Breast. Canc. Res., 2009

PJ34 causes Mitosis Arrest and Cell Death in human cancer cells measured by flow-cytometry


Mitosis Arrest and cell death in human cancer cells treated with the indicated [PJ34] (μM) for 96 hours in the indicated cells:

Pancreas- PDAC, PANC1,
Colon -DLD1, Lung
H1299, Ovary HeyA8




96 hours incubation with PJ34


Pancreas cancer PANC1




Colon cancer DLD1




Ovarian cancer HeyAB




Lung cancer H1299



PJ34 Arrests Mitosis and Induces Cell Death in Human Cancer Cells




Mitosis in Non-malignant epithelial cells treated with PJ-34 20 μ M




microtubules, centrosomes, chromosomes

Measuring changes in the post-translational modifications of proteins by the shift in their isoelectric point on pH gradient (2-D gels)



The Phenanthridine PJ34 interfered with the PTM of NuMA and kinesins kifC1/HSET and kif18A only in cancer epithelial cells: Pancreas PANC1, breast TN MDA-MB-231, lung A549, and glioblastoma U87. Other modified phenanthridines, Tiq-A and Phen had a similar but milder effect. A non-phenanthridine yet a PARP inhibitor, ABT-888, lacks this effect.




Cohen-Armon, Drug Dis. today, 2022
Cohen-Armon, cancers, 2020
Visochek et al., Oncotarget 2017


Kinesin **HSET/kifC1** is implicated in the construction of microtubules in the mitotic spindle

Kinesin **Kif18A** is implicated in the attachment of chromosomes to microtubules in the spindle mid-zone



Kinesin sliding on microtubules




α -tubulin in the microtubules (**red**);
HSET/kinesinKifC1/Kif14 (**green**)
chromosomes (**blue**)




NuMA binding to proteins is crucial for its indispensable function in the mitotic spindle



The post translational modification of NuMA is inhibited in epithelial cancer cells




PJ34 exclusively prevents the PTM of NuMA in human cancer cells: PDAC PANC1, breast TN MDA-MB-231, lung A549, and glioblastoma U87



Treatment with PJ34 exclusively prevents the co-immunoprecipitation of NuMA with proteins in cancer cells


TN breast cancer

Breast epithelial





Cohen-Armon, Drug Dis. today, 2022
Cohen-Armon, cancers, 2020
Visochek et al., Oncotarget, 2017

Aberrant spindles with un-clustered NuMA in the spindle poles in human cancer cells treated with PJ34





Treatment with PJ34

Healthy breast epithelial cells
MCF10A




Breast malignant epithelial cell
MDA-MB-231




α-tubulin
(microtubules)
NuMA

Disrupted spindle poles with dispersed chromosomes and dispersion of tankyrase1 with γ -tubulin and pericentrin in spindles of multi-centrosomal MDA-MB-231 triple-negative breast cancer cells treated with PJ34






PJ34 inhibits the activity of the **kinase pim1** and of **tankyrase1**, both modify NuMA in human cancer cells and promote its protein-binding capacity



$IC_{50}=3.7 \mu M$



Antolin AA., et al., ACS Chem Biol., 2012



$IC_{50}=1. \mu M$





Kirby CA., et al. Acta Cryst, 2012

Tankyrase1 and NuMA polyADP-ribosylation



Visocek et al., Oncotarget, 2017



Aberrant spindle poles and dispersed NuMA, centrosomes and chromosomes in multi-centrosomal TN breast cancer cells MDA-MB-231 treated with PJ34



α -tubulin
(microtubules)
Chromosomes
NuMA

kinesinC1/HSET (microtubules)
Chromosomes
 γ -tubulin (Centrosomes)

NuMA un-clustering in the spindle poles causing aberrant spindles with dispersed centrosomes and chromosomes lead to mitotic arrest in cancer cells treated with PJ34




Lara-Gonzales et al., 2012 Cur. Biol.

Persistent CyclinB1 activation of CDK





Mitosis arrest leads to
Mitotic Catastrophe cell death

Bcl-2 and Bcl_{XL} phosphorylation
by CyclinB1-activated CDK
causes Cytochrome-C leakage
and Cell Death



Cell-death during mitosis in PJ34-treated extra-centrosomal breast malignant cells TN MDA-MB-231, documented at real time by Confocal imaging. Un-clustered **centrosomes** and dispersed **chromosomes** in the cells transfected with GFP- γ -tubulin (green) and with H2B-red.



Summary

- First evidence for an exclusive modification of NuMA in cancer cells causing cell death
- A treatment causing self-eradication of malignant cells during mitosis, while healthy proliferating cells and quiescent cells are spared.
- No adverse effects were observed in nude mice, as well.
- In this mechanism, cancer cells are eradicated regardless of their genetic mutations. The more rapidly they proliferate, the more rapidly they are eradicated.

Funded by:



TAU Am. Friends



**TAU-Sheba Medical
center collaboration Fund**

Contributors:

Prof. Malka Cohen-Armon- the **Faculty of Medicine, Tel-Aviv University**

Dr. Asher Castiel

Dr. Leonid Visochek

Dr. Dana Inbar-Rozensal

Dr. Leonid Mittelman

Prof Tamar Peretz-

Head of Oncology Institute **Hadassah Medical center,
Ein Kerem, Jerusalem**

Prof. Michael Elkin- **Hadassah Medical center Ein
Kerem, Jerusalem**

Prof Shai Izraeli-

Head Pediatric Hematology Oncology
Division, **Schneider Children's Medical Center**, and
the **Faculty of Medicine, Tel-Aviv University**

Thank you